Figure - available from: Cancers
This content is subject to copyright.
Repair of BLM-induced double-strand Break and global DNA damage in cancer-free women and breast cancer survivors. The repair kinetics of BLM-induced DNA double-strand breaks was measured by neutral (A) and alkaline (B) assays. DNA double-strand breaks (A) and global damage (B) were measured in cells after BLM treatment during their recovery period at different time points. A repeated measures ANOVA was conducted to assess the impact of disease (cancer) on repair kinetics. p-values represent the statistical significance of the interaction of disease with repair activity at different time points. p < 0.05 is considered significant.
Source publication
Simple Summary
Non-Hispanic Black breast cancer survivors have poorer outcomes than White survivors, but the biological mechanisms underlying these disparities are unclear. We discovered novel race-based differences in systemic DNA damage and repair activity among breast cancer survivors. This finding suggests DNA damage and repair are important ba...
Citations
The central premise of this article is that a portion of the established relationships between social determinants of health and racial/ethnic disparities in cancer morbidity and mortality are mediated through differences in rates of biological aging processes. We further posit that using knowledge about aging could enable discovery and testing of new mechanism-based pharmaceutical and behavioral interventions (“gerotherapeutics”) to differentially improve the health of minoritized cancer survivors and reduce cancer disparities.
These hypotheses are based on evidence that lifelong differences in adverse social determinants of health contribute to disparities in rates of biological aging (“social determinants of aging”), with minoritized groups having accelerated aging (ie, a steeper slope or trajectory of biological aging over time relative to chronological age) more often than non-minoritized groups. Acceleration of biological aging can increase the risk, age of onset, aggressivity and/or stage of many adult cancers. There are also documented negative feedback loops whereby the cellular damage caused by cancer and its therapies act as drivers of additional biological aging. Together, these dynamic intersectional forces can contribute to differences in cancer outcomes between minoritized vs non-minoritized survivor populations.
We highlight key targetable biological aging mechanisms with potential applications to reducing cancer disparities and discuss methodological considerations for pre-clinical and clinical testing of the impact of gerotherapeutics on cancer outcomes in minoritized populations. Ultimately, the promise of reducing cancer disparities will require broad societal policy changes that address the structural causes of accelerated biological aging and ensure equitable access to all new cancer control paradigms.
